Most Read Posts
Cures-for-Dollars Model Comes Undone as Biotech Market Sinks
©2015 Bloomberg News NVTN8V6K50Y6 (Bloomberg) — For the last five years, biotechnology and pharmaceutical stocks have surged on an assumption about the companies that invent and sell drugs for American patients: Invent amazing treatments that save lives and cure the sick, and you can charge pretty much what you want.
Deal of the Week: Will Sprint Be Left at the Altar?
published Aug 9, 2017 5:00:07 AM, by Alex Sherman, Scott Moritz and Gerry Smith (Bloomberg) — As The Bachelorette wraps up another season, a mating dance is developing in the telecommunications world. SoftBank is desperate to find a match for Sprint, the fourth-largest U.S. wireless company, of which it owns
